Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight
Immunity, Inflammation and Disease · 2026
DOI: 10.1002/iid3.70501 ↗Kurz gefasst
Fallbericht in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Xia Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen second people's hospital clinical research Fund of shenzhen High-level hospital, shenzhen medical academy.
Abstract (Originalsprache)
Background
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may rarely coexist with malignancies such as lung cancer. Case Presentation This case report presents the first documented use of ofatumumab, a fully human anti‐CD20 monoclonal antibody, in a 75‐year‐old female with acetylcholine receptor (AChR)‐antibody‐positive generalized MG (gMG) following lung adenocarcinoma resection. Initially diagnosed with ocular MG (MGFA Class I), the patient progressed to refractory gMG (MGFA Class IIIa) post‐thymectomy and tumor resection, unresponsive to corticosteroids, tacrolimus, and intravenous immunoglobulin. Due to persistent symptoms and steroid‐induced complications, subcutaneous ofatumumab (20 mg on Days 1, 7, and 14) was administered off‐label. Rapid clinical improvement was observed, with Myasthenia Gravis Composite (MGC) and MG Activities of Daily Living (MG‐ADL) scores declining from 20 to 10 and 17 to 10, respectively, within weeks. Minimal manifestation status (MMS) was sustained for 2 years with intermittent ofatumumab re‐administration (triggered by CD19/CD20 + B‐cell reconstitution > 1%), alongside no tumor recurrence or adverse events.
Conclusion
This case highlights ofatumumab's potential efficacy and safety in managing refractory gMG post‐cancer resection, possibly via robust B‐cell depletion and reduced immunogenicity. These findings advocate for targeted B‐cell therapies as a viable strategy in complex, refractory MG cases, particularly where conventional immunosuppressants pose oncological concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
- Department of Neurology, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
- Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
- School of Public Health, Shenzhen University, Shenzhen, Guangdong, China.
- Department of Pathology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
- Huizhou First Hospital, The First Huizhou Affiliated Hospital of Guangdong Medical University, Huizhou, Guangdong, China.
ORCID-Profile: Xia Long, Yanwen Xu, Juan Xiong, Wenfeng Peng, Jinhua Qiu, Yanxia Zhou
Förderung
- Shenzhen second people's hospital clinical research Fund of shenzhen High-level hospital
- shenzhen medical academy
Zitieren
APA
Long, X., Xu, Y., Xiong, J., Peng, W., Qiu, J., & Zhou, Y. (2026). Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70501
Vancouver
Long X, Xu Y, Xiong J, Peng W, Qiu J, Zhou Y. Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70501
BibTeX
@article{Long2026,
author = {Long, Xia and Xu, Yanwen and Xiong, Juan and Peng, Wenfeng and Qiu, Jinhua and Zhou, Yanxia},
title = {Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight},
journal = {Immunity, Inflammation and Disease},
year = {2026},
doi = {10.1002/iid3.70501}
}
EUVIMED